Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report)’s share price traded down 3.5% during mid-day trading on Wednesday . The company traded as low as $3.25 and last traded at $3.35. 4,633 shares were traded during trading, a decline of 73% from the average session volume of 17,048 shares. The stock had previously closed at $3.47.
Wall Street Analyst Weigh In
Separately, Guggenheim began coverage on shares of Nanobiotix in a research note on Wednesday, August 28th. They issued a “buy” rating and a $12.00 price objective on the stock.
Check Out Our Latest Report on Nanobiotix
Nanobiotix Trading Down 3.6 %
Nanobiotix Company Profile
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Further Reading
- Five stocks we like better than Nanobiotix
- 3 Stocks to Consider Buying in October
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Dividend Capture Strategy: What You Need to Know
- 3 Penny Stocks Ready to Break Out in 2025
- How to Use High Beta Stocks to Maximize Your Investing Profits
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
